International Scholarly Research Notices

Research Article

Efficacy of Various Antidiabetic Agents as Add-On Treatments to Metformin in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis

Table 2

Summary of HbA1c (%) between the treatment and the control groups.

Study		TreatmentControlDifference
nBaselineFinalChangenBaselineFinalChangebetween groups
TZDs versus DPP IV inhs.
(i) Scott et al. [22]
Rosiglitazone versus Sitagliptin		877.73 ± 0.816.94 ± 0.75−0.79 ± 0.64917.75 ± 0.997.01 ± 0.86−0.73 ± 0.66−0.06
(ii) Bolli et al. [23]
Pioglitazone versus Vildagliptin		2958.48 ± 0.86
(SE = 0.05)		7.64 ± 1.89
(SE = 0.11)		−0.6 ± 1.12808.4 ± 0.84
(SE = 0.05)		7.73 ± 1.34
(SE = 0.08)		−0.6 ± 1.110
TZDs versus SUs
(i) Charbonnel et al. [24]
Pioglitazone versus Gliclazide		3178.71 ± 1.00NA−0.89 ± 1.29
(SE = 0.07272)		3138.53 ± 0.89NA−0.77 ± 1.18
(SE = 0.06666)		−0.12
(ii) Garber et al. [25]
Rosiglitazone versus Glibenclamide		1528.43 ± 1.207.17 ± 1.43−1.1 ± 1.30a1538.47 ± 1.256.70 ± 1.37−1.5 ± 1.29a0.4
(iii) Umpierrez et al. [26]
Pioglitazone versus Glimepiride		1078.31 ± 0.77NA−1.23 ± 0.76
(SE = 0.073)		968.40 ± 0.72NA−1.3 ± 0.75
(SE = 0.077)		0.07
(iv) Hamann et al. [27]
Rosiglitazone versus Glibenclamide, Gliclazide		2858.0 ± 0.9NA−0.78 ± 1.01
(SE = 0.06)		2888.0 ± 1.0NA−0.86 ± 1.02
(SE = 0.06)		0.08
TZD versus TZD
(i) Derosa et al. [28]
Pioglitazone versus Rosiglitazone		488.2 ± 0.86.8 ± 0.3−1.4 ± 0.7a488.1 ± 0.96.8 ± 0.5−1.3 ± 0.78a−0.1
Insulin versus SU
(i) Kvapil et al. [29]
BIAsp 30 versus Glibenclamide		1089.24 ± 1.32
(SE = 0.127)		7.52 ± 1.09
(SE = 0.105)		−1.72 ± 1.22a1149.45 ± 1.39
(SE = 0.130)		7.8 ± 1.25
(SE = 0.118)		−1.65 ± 1.33a−0.07
Data are mean ± SD values. NA: not available. aSD calculated from SD baseline and final values.